• 1
    Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004; 101: 51-57.
  • 2
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.
  • 3
    Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002; 137: 678-687.
  • 4
    Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010; 28: 2114-2122.
  • 5
    Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat. 2004; 83: 77-86.
  • 6
    Stalsberg H, Thomas DB, Rosenblatt KA, et al. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control. 1993; 4: 143-151.
  • 7
    Leach IH, Ellis IO, Elston CW. c-erb-B-2 expression in male breast carcinoma. J Clin Pathol. 1992; 45: 942.
  • 8
    Rayson D, Erlichman C, Suman VJ, et al. Molecular markers in male breast carcinoma. Cancer. 1998; 83: 1947-1955.
  • 9
    Gattuso P, Reddy VB, Green LK, Castelli MJ, Wick RM. Prognostic factors for carcinoma of the male breast. Int J Surg Pathol. 1995; 2: 199-206.
  • 10
    Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D. Status of HER-2 in male and female breast carcinoma. Am J Surg. 2001; 182: 389-392.
  • 11
    Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502.
  • 12
    Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of 4 randomized trials. J Clin Oncol. 2001; 19: 343-353.
  • 13
    Telli ML, Chang ET, Kurian AW, et al. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. 2011; 127: 471-478.
  • 14
    Bauer KR Brown M, Creech C, Schlang NC, Caggiano V. Data quality assessment of HER2 in the Sacramento region of the California Cancer Registry. J Regist Manage. 2007; 34: 4-7.
  • 15
    Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009; 15: 593-602.
  • 16
    Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med. 2003; 127: 36-41.
  • 17
    Curigliano G, Colleoni M, Renne G, et al. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Ann Oncol. 2002; 13: 895-902.
  • 18
    Arslan UY, Oksuzoglu B, Ozdemir N, et al. Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol. 2012; 29: 554-560.
  • 19
    Chavez-Macgregor M, Litton J, Chen H, et al. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer. 2010; 116: 4168-4177.
  • 20
    Sparano J, Wang W, Stears V, et al. Black race is associated with a worse outcome in patients with hormone receptor positive, Her2-normal breast cancer treated with chemohormonal therapy [abstract]. Cancer Res. 2010; 69(suppl 3). Abstract 494s.
  • 21
    O'Malley C, Shema S, White E, Glaser S. Incidence of male breast cancer in California, 1988-2000: racial/ethnic variation in 1759 men. Breast Cancer Res Treat. 2005; 93: 145-150.
  • 22
    Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005; 97: 1254-1261.
  • 23
    Neven P, Pochet N, Drijkoningen M, et al. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related. J Clin Oncol 24: 2595, 2006; author reply 2595-2597.
  • 24
    Thakkar JP, Mehta DG. A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist. 2011; 16: 276-285.
  • 25
    Yu KD, Liu GY, Di GH, et al. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. Breast. 2007; 16: 307-315.